Holen Sie sich die Stockscreener-App
2.05
1.99%
0.04
Schlusskurs vom Vortag:
$2.01
Offen:
$2.04
24-Stunden-Volumen:
36,918
Relative Volume:
0.59
Marktkapitalisierung:
$90.76M
Einnahmen:
$18.11M
Nettoeinkommen (Verlust:
$-18.95M
KGV:
-2.3768
EPS:
-0.8625
Netto-Cashflow:
-
1W Leistung:
-0.49%
1M Leistung:
-1.91%
6M Leistung:
-33.87%
1J Leistung:
+13.89%
1-Tages-Spanne:
$1.89
$2.0675
1-Wochen-Bereich:
$1.89
$2.15
52-Wochen-Spanne:
$1.60
$4.38
Adagene Inc Adr Stock (ADAG) Company Profile
Vergleichen Sie ADAG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
2.05 | 90.76M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-06-25 | Eingeleitet | China Renaissance | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten
Fmr LLC Has $2.84 Million Stock Holdings in Adagene Inc. (NASDAQ:ADAG) - Defense World
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Short Interest in Adagene Inc. (NASDAQ:ADAG) Drops By 87.8% - Defense World
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - MSN
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra - MSN
Anheuser-Busch InBev S.A. ADR falls Monday, underperforms market - MSN
Algorae Pharmaceuticals Streamlines Operations with OTCQB Exit - MSN
Anheuser-Busch InBev S.A. ADR falls Tuesday, underperforms market - MSN
Adagene shares downgraded to hold, target cut to $3.50 - Investing.com
Adagene Inc. (NASDAQ:ADAG) Sees Significant Decline in Short Interest - MarketBeat
Anheuser-Busch InBev S.A. ADR falls Friday, underperforms market - MSN
Adagene reports new findings at SITC meeting By Investing.com - Investing.com Canada
Adagene reports new findings at SITC meeting - Investing.com India
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 T - Wahanariau
Adagene Presents Two Posters with New Insights on Increased - GlobeNewswire
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 30.7% - MarketBeat
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - The Manila Times
Adagene Announces Upcoming Poster Presentations on Masked - GlobeNewswire
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year? - MSN
HC Wainwright Analysts Lift Earnings Estimates for Adagene Inc. (NASDAQ:ADAG) - MarketBeat
Adagene Inc. to Post FY2024 Earnings of ($0.78) Per Share, HC Wainwright Forecasts (NASDAQ:ADAG) - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC - Investing.com
Adagene (NASDAQ:ADAG) Receives Buy Rating from HC Wainwright - Defense World
Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC By Investing.com - Investing.com South Africa
HC Wainwright Reiterates "Buy" Rating for Adagene (NASDAQ:ADAG) - MarketBeat
Adagene reports promising cancer therapy results - Investing.com
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorect - StockTitan
Anheuser-Busch InBev S.A. ADR rises Thursday, outperforms market - MSN
Adagene to Participate in Investor Conferences in September - GlobeNewswire
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 170.8% in August - Defense World
Liquidia (NASDAQ:LQDA) vs. Adagene (NASDAQ:ADAG) Critical Contrast - Defense World
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 34.2% in July - MarketBeat
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 62.9% - Defense World
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - GlobeNewswire
Head-To-Head Survey: Altimmune (NASDAQ:ALT) vs. Adagene (NASDAQ:ADAG) - Defense World
Adagene (NASDAQ:ADAG) Rating Reiterated by HC Wainwright - MarketBeat
Finanzdaten der Adagene Inc Adr-Aktie (ADAG)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):